Bevacizumab News and Research

RSS
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

Drug combo gives lung cancer patients longer life

Drug combo gives lung cancer patients longer life

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Good results in new lung cancer treatment

Good results in new lung cancer treatment

New cancer drug Avastin keeps cancer under control

New cancer drug Avastin keeps cancer under control

Avastin available across Europe within the next few weeks

Avastin available across Europe within the next few weeks

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech announces FDA approval of Avastin manufacturing

Genentech announces FDA approval of Avastin manufacturing

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Avastin study shows significant improvement in patients with metastatic colorectal cancer